Genscript Biotech Completes Major Share Transfer in Probio Cayman

Genscript Biotech ( (HK:1548) ) has shared an update.

Genscript Biotech Corporation has completed a significant transaction involving the transfer of 300,000,000 Series A Preferred Shares of its subsidiary, Probio Cayman. This transaction, which took place on May 7, 2025, strengthens Genscript’s control over Probio Cayman, increasing its equity interest to approximately 85.09%. This strategic move is likely to enhance Genscript’s market positioning and operational capabilities in the biotech sector.

More about Genscript Biotech

Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. It focuses on providing a range of biotech services and products, with a significant emphasis on gene synthesis, protein services, and antibody development.

Average Trading Volume: 19,640,270

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$23.95B

For detailed information about 1548 stock, go to TipRanks’ Stock Analysis page.